Immuneering Appoints Leah R. Neufeld as Chief People Officer
CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq:IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activation events, today announced the appointment of Leah R. Neufeld to the newly created position of Chief People Officer, effective immediately.
Related news for (IMRX)
- Don’t Miss Out: MoBot’s Latest Stock Updates 09/10/25 02:00 PM
- Midday Movers & Shakers: Biotech Buzz, Treasury Vision & Green Tech Breakouts
- Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25
- 24/7 Market News Snapshot 10 September, 2025 – Immuneering Corporation Class A Common Stock (NASDAQ:IMRX)
- Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib